Last quarter (Q4 2023), PaxMedica, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, PaxMedica, Inc.'s net income was $-5.93M. See PaxMedica, Inc.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 16.15M	$ 16.15M	$ -10.60M	$ 7.20M	$ 5.57M	$ 598.61K
Operating Income	$ -16.15M	$ -16.15M	$ -10.60M	$ -7.20M	$ -5.57M	$ -598.61K
Net Non Operating Interest Income Expense	$ -9.16K	$ -9.16K	$ -5.74M	$ -2.81M	$ -609.46K	-
Other Income Expense	$ 2.14M	$ 2.14M	$ 226.06K	$ -225.31K	$ -1.65M	-
Pretax Income	$ -18.29M	$ -18.29M	$ -16.57M	$ -10.23M	$ -7.83M	$ -598.61K
Tax Provision	$ -34.00K	$ -34.00K	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -18.30M	$ -18.30M	$ -16.57M	$ -10.23M	$ -9.30M	$ -634.45K
Basic EPS	$ -2.36	$ -11.00	$ -1.69	$ -1.02	$ -1.27	-
Diluted EPS	$ -2.36	$ -11.00	$ -1.69	$ -1.02	$ -1.27	-
Basic Average Shares	$ 32.35M	$ 1.66M	$ 8.74M	$ 10.02M	$ 10.02M	-
Diluted Average Shares	$ 32.35M	$ 1.66M	$ 8.74M	$ 10.02M	$ 10.02M	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 16.15M	$ 16.15M	$ -10.60M	$ 7.20M	$ 5.57M	$ 598.61K
Net Income From Continuing And Discontinued Operation	$ -18.30M	$ -18.30M	$ -16.57M	$ -10.23M	$ -7.83M	$ -598.61K
Normalized Income	$ -9.94M	$ -18.32M	-	$ -9.83M	$ -6.23M	$ -598.61K
Interest Expense	-	-	-	$ 2.81M	$ 609.46K	-
EBIT	$ -18.28M	$ -18.28M	$ -16.56M	$ -7.42M	$ -7.22M	$ -598.61K
EBITDA	$ -18.28M	$ -18.28M	$ -16.56M	$ -7.42M	$ -7.22M	$ -598.61K

Currency in USD

PaxMedica, Inc. Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing